Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0364)
Name |
Ferroptocide
|
||||
---|---|---|---|---|---|
Synonyms |
Ferroptocide; CHEMBL5075911; CHEBI:173106; (2S,3aS,4S,5R,7R,8S,8aS,9R)-5-(1,3-dioxo-2-phenyl-2,3,5,8-tetrahydro-1H-[1,2,4]triazolo[1,2-a]pyridazin-6-yl)-2,8a-dihydroxy-4,8,9-trimethyl-1-oxooctahydro-1H-3a,8-propanoazulen-7-yl chloroacetate
Click to Show/Hide
|
||||
Structure |
![]() |
||||
Formula |
C30H36ClN3O7
|
||||
IUPAC Name |
[(1S,3S,5S,6S,7R,9R,10S,13R)-9-(1,3-dioxo-2-phenyl-5,8-dihydro-[1,2,4]triazolo[1,2-a]pyridazin-6-yl)-3,5-dihydroxy-6,10,13-trimethyl-4-oxo-7-tricyclo[4.4.3.01,5]tridecanyl] 2-chloroacetate
|
||||
Canonical SMILES |
CC1CCC23CC(C(=O)C2(C1(C(CC(C3C)C4=CCN5C(=O)N(C(=O)N5C4)C6=CC=CC=C6)OC(=O)CCl)C)O)O
|
||||
InChI |
InChI=1S/C30H36ClN3O7/c1-17-9-11-29-14-22(35)25(37)30(29,40)28(17,3)23(41-24(36)15-31)13-21(18(29)2)19-10-12-32-26(38)34(27(39)33(32)16-19)20-7-5-4-6-8-20/h4-8,10,17-18,21-23,35,40H,9,11-16H2,1-3H3/t17-,18+,21-,22+,23-,28+,29+,30-/m1/s1
|
||||
InChIKey |
LLYJISDUHFXOHK-GOCONZMPSA-N
|
||||
PubChem CID |
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 1 item(s) under this Target | ||||
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
Responsed Disease | Breast cancer | ICD-11: 2C60 | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | |||
In Vitro Model | ES-2 cells | Ovarian clear cell adenocarcinoma | Homo sapiens | CVCL_3509 |
HCT 116 cells | Colon carcinoma | Homo sapiens | CVCL_0291 | |
4T1 cells | Mammary carcinoma | Mus musculus | CVCL_0125 | |
A-549 cells | Lung adenocarcinoma | Homo sapiens | CVCL_0023 | |
MCF-10A cells | Normal | Homo sapiens | CVCL_0598 | |
HFF-1 cells | Normal | Homo sapiens | CVCL_3285 | |
Response regulation | As ferroptocide induces a regulated, non-apoptotic mode of cell death, this compound (and possibly other pro-ferroptotic agents) have the potential to synergize with the immune system for the treatment of breast cancer. | |||